Genewiz, a South Plainfield, NJ-based global genomics services provider, raised a funding round of undisclosed amount.
The round was led by OrbiMed, with participation from Ampersand Capital Partners and Prime Value Capital Management (PVCM). In conjunction with the funding, Dr. Jonathan Wang, Senior Managing Director, OrbiMed Asia, joined Genewiz’s Board of Directors.
The company intends to use the funds to conduct growth activities.
Led by Dr. Steve Sun, Co-Founder, Chairman and CEO, and Dr. Amy Liao, Co-Founder, President and COO, Genewiz provides DNA sequencing, gene synthesis, molecular biology, high throughput/next generation sequencing, bioinformatics, and GLP-CLIA regulatory services to pharmaceutical and biotechnology companies, as well as research facilities within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions around the world.
The company has a global network of laboratories in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; and Tokyo, Japan.